David Richards is the founder of Clarametyx Biosciences. Clarametyx Biosciences has raised $51M in total funding. Latest round: Series A.
David V. Richards is the Chief Executive Officer of Clarametyx Biosciences, a preclinical biotechnology company. He was appointed CEO in 2021 and has led the company through its Series A financing round in January 2024. Under his leadership, the company completed a Phase 2a study for its lead monoclonal antibody candidate CMTX-101 and received Fast Track and QIDP designations from the FDA.
Full founder directory · Investor directory · Company funding database · Fundraising library